Viatris (VTRS) Change in Account Payables (2020 - 2026)
Viatris (VTRS) recorded quarterly Change in Account Payables of $32.7 million in Q1 2026, up 76.76% quarter-over-quarter from $18.5 million in Q4 2025, and down 67.81% on a YoY basis from $101.6 million in Q1 2025.
Viatris (VTRS) Change in Account Payables (2020 - 2026) Analysis & Trends
Viatris' Change in Account Payables history runs 7 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 67.81% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at -$236.9 million (down 57.62% YoY), while the FY2025 annual figure was -$168.0 million, down 566.67% from the prior year.
- Change in Account Payables was $32.7 million for Q1 2026 at Viatris, up from $18.5 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $287.9 million in Q1 2024 to a low of -$329.9 million in Q3 2022.
- Historically, Change in Account Payables has averaged $22.7 million across 5 years, with a median of $32.7 million in 2026.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables soared 707.28% in 2023, then slumped 2590.32% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $245.6 million in 2022, then tumbled by 68.08% to $78.4 million in 2023, then sank by 41.71% to $45.7 million in 2024, then sank by 59.52% to $18.5 million in 2025, then soared by 76.76% to $32.7 million in 2026.
- The last three Change in Account Payables figures came in at $32.7 million (Q1 2026), $18.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 62.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 167.64 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 190,000.00 |
| 10 | Viatris | - | - | 1.16 Bn | 32.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.70 Mn |
| Mar 31, 2026 | 32.70 Mn |
| Dec 31, 2025 | 18.50 Mn |
| Dec 31, 2025 | 18.50 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | -291.30 Mn |
| Jun 30, 2025 | -291.30 Mn |
| Mar 31, 2025 | 101.60 Mn |
| Mar 31, 2025 | 101.60 Mn |
| Dec 31, 2024 | 45.70 Mn |
| Dec 31, 2024 | 45.70 Mn |
| Sep 30, 2024 | -66.00 Mn |
| Sep 30, 2024 | -66.00 Mn |
| Jun 30, 2024 | -231.60 Mn |
| Jun 30, 2024 | -231.60 Mn |
| Mar 31, 2024 | 287.90 Mn |
| Mar 31, 2024 | 287.90 Mn |
| Dec 31, 2023 | 78.40 Mn |
| Dec 31, 2023 | 78.40 Mn |